New Option Soon for Some European Patients With Leukemia New Option Soon for Some European Patients With Leukemia

Gilteritinib has been recommended for approval for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation.International Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news